What is the projected market valuation for the HER2 Positive Breast Cancer Treatment Market in 2035?

The HER2 Positive Breast Cancer Treatment Market is projected to reach a valuation of 53.53 USD Billion by 2035. Read More

What was the market valuation for the HER2 Positive Breast Cancer Treatment Market in 2024?

In 2024, the market valuation for HER2 Positive Breast Cancer Treatment was 34.62 USD Billion. Read More

What is the expected CAGR for the HER2 Positive Breast Cancer Treatment Market from 2025 to 2035?

The expected CAGR for the HER2 Positive Breast Cancer Treatment Market during the forecast period 2025 - 2035 is 4.04%. Read More

Which companies are the key players in the HER2 Positive Breast Cancer Treatment Market?

Key players in the market include Roche, Pfizer, AstraZeneca, Novartis, Merck & Co, GSK, Bristol-Myers Squibb, Eli Lilly, and Amgen. Read More

What are the projected revenues for Monoclonal Antibodies in the HER2 Positive Breast Cancer Treatment Market by 2035?

Monoclonal Antibodies are projected to generate revenues between 18.0 USD Billion by 2035. Read More

How does the revenue for Targeted Therapy compare to Chemotherapy in 2035?

By 2035, Targeted Therapy is expected to generate revenues of 16.0 USD Billion, surpassing Chemotherapy's projected 12.0 USD Billion. Read More

What is the anticipated revenue for Ado-trastuzumab Emtansine by 2035?

Ado-trastuzumab Emtansine is anticipated to reach revenues of 14.53 USD Billion by 2035. Read More

What segment is expected to have the highest revenue in the HER2 Positive Breast Cancer Treatment Market by 2035?

The segment for Subcutaneous administration is expected to have the highest revenue, projected at 20.53 USD Billion by 2035. Read More

What revenue is expected from the Early Stage cancer treatment segment by 2035?

The Early Stage cancer treatment segment is expected to generate revenues of 15.0 USD Billion by 2035. Read More

How does the revenue for Locally Advanced Stage cancer treatment compare to Metastatic Stage treatment by 2035?

By 2035, Locally Advanced Stage treatment is projected to generate 18.0 USD Billion, while Metastatic Stage treatment is expected to reach 20.53 USD Billion. Read More

Her2 Positive Breast Cancer Treatment Market

ID: MRFR/HC/35522-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

HER2 Positive Breast Cancer Treatment Market Research Report By Treatment Type (Monoclonal Antibodies, Chemotherapy, Targeted Therapy, Hormonal Therapy), By Drug Class (Trastuzumab, Pertuzumab, Lapatinib, Ado-trastuzumab Emtansine), By Administration Route (Intravenous, Oral, Subcutaneous), By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Her2 Positive Breast Cancer Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.04%

2024 Market Size$ 34.62 Billion

2025 Market Size$ 36.02 Billion

2035 Market Size$ 53.53 Billion

Key Players

Roche

Pfizer

AstraZeneca

Novartis

Merck & Co

GSK

Trends

Emergence of Novel Therapeutics
Increased Focus on Early Detection
Integration of Digital Health Solutions

Opportunities

Advancements in Targeted Therapies
Increased Investment in Cancer Research
Growing Awareness and Education Initiatives

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Monoclonal Antibodies
  2. 4.1.2 Chemotherapy
  3. 4.1.3 Targeted Therapy
  4. 4.1.4 Hormonal Therapy
2. 4.2 Healthcare, BY Drug Class (USD Billion)
  1. 4.2.1 Trastuzumab
  2. 4.2.2 Pertuzumab
  3. 4.2.3 Lapatinib
  4. 4.2.4 Ado-trastuzumab Emtansine
3. 4.3 Healthcare, BY Administration Route (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Oral
  3. 4.3.3 Subcutaneous
4. 4.4 Healthcare, BY Stage of Cancer (USD Billion)
  1. 4.4.1 Early Stage
  2. 4.4.2 Locally Advanced Stage
  3. 4.4.3 Metastatic Stage
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GSK (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY DRUG CLASS
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 US MARKET ANALYSIS BY STAGE OF CANCER
7. 6.7 CANADA MARKET ANALYSIS BY TYPE
8. 6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
9. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
10. 6.10 CANADA MARKET ANALYSIS BY STAGE OF CANCER
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY DRUG CLASS
14. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
15. 6.15 GERMANY MARKET ANALYSIS BY STAGE OF CANCER
16. 6.16 UK MARKET ANALYSIS BY TYPE
17. 6.17 UK MARKET ANALYSIS BY DRUG CLASS
18. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
19. 6.19 UK MARKET ANALYSIS BY STAGE OF CANCER
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY DRUG CLASS
22. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
23. 6.23 FRANCE MARKET ANALYSIS BY STAGE OF CANCER
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY DRUG CLASS
26. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
27. 6.27 RUSSIA MARKET ANALYSIS BY STAGE OF CANCER
28. 6.28 ITALY MARKET ANALYSIS BY TYPE
29. 6.29 ITALY MARKET ANALYSIS BY DRUG CLASS
30. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
31. 6.31 ITALY MARKET ANALYSIS BY STAGE OF CANCER
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY DRUG CLASS
34. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
35. 6.35 SPAIN MARKET ANALYSIS BY STAGE OF CANCER
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY STAGE OF CANCER
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE
42. 6.42 CHINA MARKET ANALYSIS BY DRUG CLASS
43. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
44. 6.44 CHINA MARKET ANALYSIS BY STAGE OF CANCER
45. 6.45 INDIA MARKET ANALYSIS BY TYPE
46. 6.46 INDIA MARKET ANALYSIS BY DRUG CLASS
47. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
48. 6.48 INDIA MARKET ANALYSIS BY STAGE OF CANCER
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY DRUG CLASS
51. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
52. 6.52 JAPAN MARKET ANALYSIS BY STAGE OF CANCER
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY STAGE OF CANCER
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
59. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
60. 6.60 MALAYSIA MARKET ANALYSIS BY STAGE OF CANCER
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY DRUG CLASS
63. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
64. 6.64 THAILAND MARKET ANALYSIS BY STAGE OF CANCER
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY DRUG CLASS
67. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
68. 6.68 INDONESIA MARKET ANALYSIS BY STAGE OF CANCER
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
71. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
72. 6.72 REST OF APAC MARKET ANALYSIS BY STAGE OF CANCER
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY DRUG CLASS
76. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
77. 6.77 BRAZIL MARKET ANALYSIS BY STAGE OF CANCER
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY DRUG CLASS
80. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
81. 6.81 MEXICO MARKET ANALYSIS BY STAGE OF CANCER
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
84. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
85. 6.85 ARGENTINA MARKET ANALYSIS BY STAGE OF CANCER
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY STAGE OF CANCER
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY STAGE OF CANCER
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY STAGE OF CANCER
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
101. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
102. 6.102 REST OF MEA MARKET ANALYSIS BY STAGE OF CANCER
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Her2 Positive Breast Cancer Treatment Market Segmentation

Her2 Positive Breast Cancer Treatment Market By Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Chemotherapy
Targeted Therapy
Hormonal Therapy

Her2 Positive Breast Cancer Treatment Market By Drug Class (USD Billion, 2025-2035)

Trastuzumab
Pertuzumab
Lapatinib
Ado-trastuzumab Emtansine

Her2 Positive Breast Cancer Treatment Market By Administration Route (USD Billion, 2025-2035)

Intravenous
Oral
Subcutaneous

Her2 Positive Breast Cancer Treatment Market By Stage of Cancer (USD Billion, 2025-2035)

Early Stage
Locally Advanced Stage
Metastatic Stage

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”